IGM Biosciences saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of IGM Biosciences’s patent filings and grants. Buy the databook here.
IGM Biosciences has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with two publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 67% of filings. The World Intellectual Property Organization(WIPO), United States(US), and Israel(IL) patent Office are among the top ten patent offices where IGM Biosciences is filings its patents. Among the top granted patent authorities, IGM Biosciences has 100% of its grants in Israel(IL).
Amgen and Roche could be the strongest competitors for IGM Biosciences
Autoimmune disorders related patents lead IGM Biosciences portfolio followed by inflammation
IGM Biosciences has highest number of patents in autoimmune disorders followed by inflammation.
For comprehensive analysis of IGM Biosciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.